Tradestie Institutional Equity Comparison Engine

GRML vs BMGL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMGL Overall Edge

BMGL Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Basel Medical Group Ltd Ordinary Shares (BMGL) driven by superior Growth & Margin while GRML counters with relative strength in Momentum & Technical. Fundamentally, GRML trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BMGL at N/M Forward P/E and -3.7% operating margin (+63.0% YoY). In options structure, GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BMGL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
GRML N/M vs BMGL N/M Fwd P/E
Growth & Margin Winner BMGL
Op Margin N/A vs -3.7% ยท YoY N/A vs +63.0%
Momentum & Technical Winner GRML
1Y +650.0% vs -79.0% ยท 52W Pos 19% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
1M Return -41.5%
1Y Return +650.0%
Forward P/E N/M
Unified AI Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
BMGL NASDAQ
Basel Medical Group Ltd Ordinary Shares
Services-Offices & Clinics Of Doctors Of Medicine
$0.31
-33.55% 1D
Market Cap $7.7M
1M Return -92.09%
1Y Return -79.04%
Forward P/E N/M
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GRML +650.0% BMGL -79.04% Spread: +697.68 pp (GRML Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GRML TTM Op. Margin: N/A BMGL TTM Op. Margin: -3.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs BMGL. Trailing 12-month operating profitability (GRML N/A vs BMGL -3.7%) and valuation multiples (GRML N/M vs BMGL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GRML (3) vs BMGL (5)
Institutional Metric GRML BMGL Criterion Row Winner
Market Capitalization Scale N/A $7.7M Larger Scale BMGL
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +63.0% Higher Growth BMGL
Operating Margin (TTM) Profitability N/A -3.7% Higher Margin BMGL
Net Profit Margin Profitability N/A -3.5% Higher Margin BMGL
Return on Equity (ROE) Capital Efficiency N/A -28.7% Higher ROE BMGL
52-Week Range Position Momentum 19% ($0โ€“$18) 0% ($0โ€“$11) Stronger Trend GRML
Beta / 30D Volatility Risk Regime -5.32ฮฒ ยท 95% Vol -2.08ฮฒ ยท 332% Vol Lower Realized Risk GRML
Unified Institutional Score Composite Signal 56.8 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite GRML

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GRML vs BMGL Buy Guide
GRML UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GRML Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BMGL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BMGL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GRML nor BMGL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.